Endocan, a Potential Biomarker of Endothelial Dysfunction: A Brief Overview

Area of Science:

• Biochemistry
• Vascular Biology
• Biomarker Discovery

Background:

• Endocan (endothelial cell-specific molecule 1, ESM-1) is an endothelium-derived proteoglycan.
• It regulates endothelial cell functions like adhesion, migration, and proliferation.
• Elevated serum endocan indicates endothelial activation and dysfunction, common in inflammatory and autoimmune conditions.

Purpose of the Study:

• To review the role of endocan in various diseases.
• To explore endocan's association with endothelial dysfunction and clinical outcomes.
• To assess endocan's potential as a diagnostic and prognostic biomarker.

Main Methods:

• Literature review of studies reporting endocan levels, disease markers, and clinical outcomes.
• Analysis of endocan's correlation with specific conditions: hypertension (HTN), cirrhosis, diabetes, peripheral arterial disease (PAD), COVID-19, erectile dysfunction (ED), and psoriasis vulgaris.
• Synthesis of findings regarding endocan's association with endothelial dysfunction and disease severity.

Main Results:

• Elevated endocan levels are associated with endothelial dysfunction in diabetes, HTN, PAD, ED, and psoriasis.
• Endocan correlates with disease severity in cirrhosis, PAD, and psoriasis vulgaris.
• COVID-19 studies suggest endocan is linked to coronavirus-induced endotheliitis.
• Endocan's role in promoting inflammation and fibrosis is observed in HTN and cirrhosis.

Conclusions:

• Endocan is a significant biomarker for endothelial dysfunction across multiple pathologies.
• Monitoring endocan levels may aid in disease management and prognosis prediction.
• Further research is needed to fully elucidate endocan's clinical utility.